

5

Claims

1. Use of an inhibitor comprising plasma membrane calcium ATPase (PMCA) to inhibit sperm mobility to achieve contraception.

10

2. Use according to Claim 1, wherein the inhibitor is directed against any one of the four isoforms of plasma membrane calcium ATPase PMCA.

15

3. Use according to Claim 1, wherein the inhibitor is directed against the PMCA4 isoform.

20

4. Use according to Claims 1 - 3, wherein the inhibitor is 5- or 6-carboxyeosindiacetate succinimidyl ester or an eosin or fluorescein or a derivative thereof.

5. Use according to Claims 1 - 3, wherein the inhibitor is caloxin 2a1 or a derivative thereof.

25

6. Use according to Claims 1 - 3, wherein the inhibitor is spermin or a derivative thereof.

30

7. Use according to Claims 1 - 6, wherein the inhibitor is administered orally, parenterally or as a coated mechanical contraceptive.

35

8. Use according to Claims 1 - 7, wherein the inhibitor is administered for single-use contraception or chronically as a contraceptive.
9. Use according to Claims 1 - 8, wherein the inhibitors are administered to a mammal, preferably to a human being.

- 5 10. Contraceptive containing a PMCA inhibitor in combination
with a pharmaceutically acceptable carrier.
11. Contraceptive according to Claim 10, wherein the
contraceptive is present in combination with a
10 conventional contraceptive.
12. Contraceptive according to Claim 11, wherein the
conventional contraceptive is a condom.
- 15 13. Method for infertility diagnosis in the case of a human
male, wherein the diagnosis is based on the detection of a
mutation or a post-translational modification of a PMCA
coding gene.